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Abstract: Optimal research results rely on the selection of cellular models capable of recapitulating
the characteristics of primary tumours from which they originate. The expression of mucins (MUC16
and MUC1) and truncated O-glycans (Tn, STn and T) represents a characteristic footprint of serous
ovarian carcinomas (SOCs). Therefore, selecting ovarian cancer (OVCA) cell lines that reflect this
phenotype is crucial to explore the putative biological role of these biomarkers in the SOC setting.
Here, we investigated a panel of OVCA cell lines commonly used as SOC models, and tested whether,
when cultured in 2D and 3D conditions, these recapitulate the mucin and O-glycan expression profiles
of SOCs. We further explored the role of truncating the O-glycosylation capacity in OVCAR3 cells
through knockout of the COSMC chaperone, using in vitro and in vivo assays. We found that the
majority of OVCA cell lines of serous origin do not share the mucin and truncated O-glycan footprint
of SOCs, although 3D cultures showed a higher resemblance. We also found that genetic truncation
of the O-glycosylation capacity of OVCAR3 cells did not enhance oncogenic features either in vitro
or in vivo. This study underscores the importance of well-characterized cellular models to study
specific features of ovarian cancer.
Keywords: serous ovarian carcinomas; ovarian cancer cell lines; MUC16; MUC1; truncated
O-glycans; COSMC
1. Introduction
Cancer cell lines have been used for decades as elective in vitro models in cancer research.
Despite the ubiquitous use of cancer cell line models, one question remains since the first cell line
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was isolated in the 1950s [1]: How well do in vitro cell line models reproduce the tumour features?
The selection of well-characterized cancer cell lines that better mimic the tumour of origin is crucial
to deliver precise results. Several studies have pointed out the need for good cell line models
of the distinct histological subtypes of ovarian cancer (OVCA) [2,3]. Epithelial ovarian cancer is
a highly heterogeneous disease [4], with serous ovarian carcinoma (SOC) being responsible for ~70%
of epithelial ovarian cancers [5]. Unfortunately, we have imprecise/conflicting information on the
histological subtype of the original primary tumour for the most commonly used OVCA cell lines,
which limits proper selection of cell lines for studies [6]. A comparative study based on copy-number,
mutations, and mRNA expression profiles revealed that most OVCA cell lines widely used as SOC
models do not reproduce the molecular features of serous origin [7]. Another important aspect of
in vitro cell models is the culture conditions, where 3D cell culture systems are now widely accepted
as more representative models that better reflect gene and protein expression patterns as well as
microRNA and metabolic profiles of the tumours, as compared to 2D monolayer cultures [8,9].
Previously, we showed that most SOC express mucins MUC16 and MUC1 and truncated
O-glycans, Tn (GalNAcα1-O-Ser/Thr), STn (NeuAcα2–6GalNAcα1-O-Ser/Thr) and T (Galβ1–3GalNAcα1-
O-Ser/Thr [10]. Furthermore, we identified the expression of Tn and STn as being highly specific for
these malignant conditions. Here, we investigated whether the OVCA cell lines commonly used as
SOC models, cultured in 2D and 3D conditions, reproduce the mucin and O-glycan expression profiles
of SOCs. Additionally, we explored whether the expression of Tn and STn glycoforms has an impact
on the biological behaviour of OVCA cells. To this end we used a previously established isogenic cell
model of OVCAR3 SimpleCells (SC) [11]. OVCAR3 SC were genetically engineered to express truncated
Tn and STn O-glycans. This was archived by knocking out the COSMC gene [12], a private chaperone
for the core1 O-glycan elongation enzyme C1GalT1 [13,14], thus generating homogenous expression of
Tn and STn truncated O-glycans. The models generated were tested using in vitro and in vivo assays.
We found that the majority of OVCA cell lines of serous origin do not express the characteristic
mucin and O-glycan footprint of SOCs. Moreover, we found that genetic truncation of O-glycosylation
in OVCAR3 cells expressing MUC16 and MUC1 did not enhance oncogenic features in vitro or in vivo
in xenografts. Our study underscores the importance of well-characterized cellular models to study
specific features of ovarian tumours.
2. Results
2.1. Expression of MUC16, MUC1, and Truncated O-Glycans in a Panel of Ovarian Cancer Cell Lines
We studied the expression of mucins MUC16 and MUC1 and truncated O-glycans Tn, STn and
T by immunocytochemistry in eight OVCA cell lines derived from different peritoneal cavity sites,
in 2D and 3D culture conditions (Figure 1A). The expression profile of studied mucins and truncated
O-glycans was not associated with the site of origin of OVCA cell lines (Figure 1C and Table S1).
For example, OVCAR8 (derived from primary tumour in the ovary), SKOV3 (derived from ascitic
fluid) and EFO27 (derived from omentum metastasis) presented the same immunophenotype without
expression of MUC16, MUC1, Tn, STn, and T.
The number of positive cell lines and the percentage of positive cells for the studied biomarkers
(MUC16, MUC1, Tn, STn, and T) was in general higher in 3D cultures. MUC16 was expressed in
a higher number of cells from cell lines OVCAR3 and OVCAR4 in 3D cultures, but no differences were
observed regarding the number of positive cell lines. MUC1 expression was present in 4/8 (50.0%)
cell lines in 2D cultures and in 6/8 (75.0%) cell lines in 3D cultures. Truncated O-glycan expression
in 2D cultures was 1/8 (12.5%) for Tn, 3/8 (37.5%) for STn, and 1/8 (12.5%) for T. In 3D cultures,
the expression of Tn and T increased 3- to 4-fold compared with 2D cultures. For STn, we only observed
an increase in the numbers of cell stained for STn in an OVCAR4 cell line.
Expression levels in 3D cultures were lower than those presented by tumour tissues. In the 23 SOCs
previously studied by us [10] (Figure 1B), MUC16 expression was observed in 23/23 (100%) tumours,
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MUC1 in 20/23 (87.0%), and truncated O-glycans expression was present in 18/23 (78.3%) for Tn,
21/23 (91.3%) for STn, and 20/23 (87.0%) for T [10]. In the same paper, a validation series of 55 cases from
a different hospital was analysed, and similar results were obtained for the footprint profile of SOC [10].
From the cell lines studied, the OVCAR3, OVCAR4, and OVCAR5 cell lines were the ones presenting
a pattern of expression closer to the SOCs. On the other hand, OVCAR8 was negative for all evaluated
mucins and O-glycans (Figure 2). Additionally, using a different 3D culture method with continuous
agitation [15], we observed an increased percentage of positive cells for tested markers within each cell
line, but no differences were observed regarding the number of positive and negative cell lines (Figure S1).
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Figure 2. Expression of MUC16, MUC1, Tn, STn, and T in OVCAR3 and OVCAR8 cell lines, cultured 
in 2D and 3D conditions, assessed by immunocytochemistry. Scale bar, 200 μm. 
Figure 1. Expression of MUC16, MUC1, and truncated O-glycans in a panel of ovarian cancer cell
lines. (A) Expression profile of MUC16, MUC1, Tn, STn, and T by immunocytochemistry in eight
OVCA cell lines cultured in 2D and 3D conditions; (B) Expression pattern of the same mucins and
truncated O-glycans in a series of 23 SOCs previously reported by us [10]; the colour key represents the
percentage of positive cells for each marker; (C) Representation of the origin of ovarian cancer cell lines
(adapted from © Macmillan Cancer Support 2018).
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2.2. Truncated O-Glycans Reduce Proliferation while Increasing Apoptosis and Cell Migration
In order to explore the role of Tn and STn expression in OVCA, we used an isogenic OVCAR3 SC
cell line model [11], which is genetically engineered to have impaired O-glycan elongation by KO of
the core1 synthase chaperone, COSMC, resulting in homogeneously truncated Tn and STn O-glycans
expression (Figure S2).
Effects of COSMC KO on cell proliferation and apoptosis were analysed by flow cytometry
analysis of BrdU and Annexin V/Pi positive cells, respectively. As shown in Figure 3A, a significant
decrease in cell proliferation and increase in apoptosis were observed in OVCAR3 SC compared with
parental OVCAR3. To determine whether the homogeneous expression of Tn and STn modified the
capacity of OVCAR3 cells to migrate, we performed wound healing assays (random cell motility).
A significant increase in random cell migration was observed in OVCAR3 SC compared with parental
OVCAR3 cells (Figure 3B). We also evaluated the invasive properties (directed cell motility) in both cell
lines using the transwell chamber assay containing an extracellular matrix layer (Matrigel). As shown
in Figure 3B, no significant differences were observed between OVCAR3 SC and the corresponding
parental cell line.
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mesothelial cell layer covering these organs. Electron microscopy studies of OVCA nodules attached 
to peritoneal cavity organs revealed that mesothelial cells are not present directly under the tumour 
mass,  suggesting  mesothelial  clearance  from  the  area  beneath  the  tumour  [16,17].  Mesothelial 
clearance assays have been used as an  in vitro co‐culture model  to evaluate  the ability of OVCA 
aggregates to attach and spread on mesothelial monolayers [18,19]. To investigate if the homogenous 
Figure 3. Truncated O-glycans affect the biological behaviour of OVCAR3 cells. (A) Flow cytometry
analysis of cell proliferation (left) and apoptosis (right), quantified by BrdU and Annexin V/Pi positive
cells, respectively. Significantly decreased proliferation was observed in OVCAR3 SC compared with
parental OVCAR3 at 48 and 72 h after seeding. Significantly increased apoptosis was observed in
OVCAR3 SC compared with parental OVCAR3 at 72 h after seeding; (B) Migratory (left) and invasive
(right) properties of OVCAR3 and OVCAR3 SC, quantified following wound-healing assays and
invasion through Matrigel, respectively. Significantly increased migration was observed in OVCAR3 SC
compared with parental OVCAR3. No significant differences were observed in the invasive properties
of OVCAR3 SC compared with parental OVCAR3. All experiments were performed in triplicate in at
least two independent experiments. Values represent the mean ± SD, * p < 0.05, ** p < 0.01.
2.3. O-Glycosylation Capacity Affects the Mesothelial Clearance of OVCAR3
The formation of peritoneal implants depends on the ability of OVCA cell clusters to attach to
organs within the peritoneal cavity, a process that requires adhesion to and invasion through the
mesothelial cell layer covering these organs. Electron microscopy studies of OVCA nodules attached to
peritoneal cavity organs revealed that mesothelial cells are not present directly under the tumour mass,
suggesting mesothelial clearance from the area beneath the tumour [16,17]. Mesothelial clearance
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assays have been used as an in vitro co-culture model to evaluate the ability of OVCA aggregates to
attach and spread on mesothelial monolayers [18,19]. To investigate if the homogenous expression of
Tn and STn O-glycans alters the mesothelial clearance capacity of OVCA aggregates, we co-cultured
aggregates of parental OVCAR3 and SC with monolayers of mesothelial cells stably expressing EGFP
protein (MeT5A-EGFP). As shown in Figure 4 and Supplementary Videos S1 and S2, OVCAR3 SC
cleared mesothelial cells significantly less efficiently compared to the clearance achieved by parental
OVCAR3 cells. We also observed that OVCAR3 SC have less ability to form well-defined aggregates
compared with parental OVCAR3 (Figure S3), which can be related to the decreased mesothelial
clearance observed in OVCAR3 SC. These data suggest that elongated O-glycans play a role in
aggregate formation and the ability of OVCAR3 cells to breach the mesothelium.
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Both parental OVCAR3 and SC were efficient to form tumours in mice. Regarding the size of the 
tumours,  parental  OVCAR3  xenografts  presented  macroscopically  perceptible  tumours  in  the 
peritoneal cavity (Figure 5A), while OVCAR3 SC only presented microscopic tumours (Figure 5B). The 
Figure 4. O-glycosylation capacity affects mesothelial clearance of OVCAR3. (A) Representative images
from mesothelial clearance assays of OVCAR3 (upper) and OVCAR3 SC (bottom), taken at 0 and 18 h
of co-culture; (B) Quantification of mesothelial clearance in parental OVCAR3 and OVCAR3 SC with
a significant decrease of mesothelial clearance in OVCAR3 SC. The clearance area was measured
by co-culturing aggregates of ovarian cancer cells with MeT5A-EGFP mesothelial cell monolayers.
After 18 h of co-culture, the negative space created in the mesothelial monolayer by the ovarian cancer
aggregates was measured and divided by the initial size of the ovarian cancer aggregates at time
0 to determine the normalized clearance area. More than eight aggregates were scored over three
independent experiments. Scale bar, 20 µm. Values represent the mean ± SD, **** p < 0.0001.
2.4. OVCAR3 Xenografts Formed Larger Tumours than OVCAR3 SC
To analyse the effect of altered O-glycosylation in OVCAR3 on tumour formation, tumour growth,
and invasive capacity, we established intraperitoneal (i.p.) xenografts of parental OVCAR3 and
OVCAR3 SC. After eight weeks, some mice presented abdominal distension, which predicts peritoneal
carcinomatosis and/or ascites, and all mice were sacrificed. After necropsies, abdominal tissues were
harvested and fixed in formalin, and histological processing was performed for microscopic analysis of
tumour growth and invasiveness. Haematoxylin and eosin (H&E) of the uterus and ovaries, peritoneal
wall, pancreas, liver, peripheral lymph nodes, and lungs were examined as typical locations for tumour
implants and metastasis.
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Both parental OVCAR3 and SC were efficient to form tumours in mice. Regarding the size of the
tumours, parental OVCAR3 xenografts presented macroscopically perceptible tumours in the peritoneal
cavity (Figure 5A), while OVCAR3 SC only presented microscopic tumours (Figure 5B). The majority of
tumour implants was found to be adherent to the surface of peritoneal organs (the ovaries, peritoneal
wall, pancreas, and liver) in xenografts of both cell lines. Metastases within the peritoneal cavity were
observed in the same number of animals and localized in the ovary, peritoneum, pancreas, and liver
capsule for both parental OVCAR3 and SC (5/5). However, lymphatic/haematogenous metastases
of parental OVCAR3 cells were identified in the lymph nodes of 2/5 xenografts and in the lung of
4/5 xenografts, whereas OVCAR3 SC cells were only identified in the lungs of 2/5 mice (Figure 5C).
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Figure 5. OVCAR3 xenografts formed larger tumours than OVCAR3 SC. (A) OVCAR3 xenografts
formed large tumours in the peritoneum and in the Douglas Sac (arrow). Representative metastatic
sites shown by H&E stain of lung, liver, and ovary. Immunocytochemistry showing the expression of
T antigen of parental OVCAR3 cells in the peritoneum. Arrows indicate areas of tumour aggregates;
(B) OVCAR3 SC xenografts formed smaller tumours compared with parental OVCAR3. Representative
metastatic sites shown by H&E stain of lung, liver, and ovary. Immunocytochemistry showing the
absence of T antigen expression of OVCAR3 SC cells in the peritoneum. Arrows indicate areas of tumour
aggregates; (C) The number of animals with metastasis in the ovary, peritoneum, pancreas, and liver
capsule was the same for both cell lines (5/5). OVCAR3 were identified in the lymph nodes of 2/5
mice and in the lungs of 4/5 mice. OVCAR3 SC were absent in the lymph nodes and present in the
lung of 2/5 mice. A total of five mice were used per condition. The scale bar on microscopic images
represents 200 µm.
3. Discussion
Expression of the mucins MUC16 and MUC1 in combination with the truncated O-glycans
Tn, STn, and T is a phenotype observed in ~70% of SOCs [10]. In order to analyse and compare
the expression of these biomarkers in tumour tissues retrieved from pathology archives with the
expression in cultured cell lines, it is essential to clarify possible discrepancies arising from different
pre-analytical conditions (fixation and histological processing methods) that may influence protein
and O-glycan detection [20,21]. Therefore, we used formalin-fixed and paraffin-embedded cell lines
for the immunocytochemistry procedure. Our results showed that within the panel of OVCA cell lines
studied, OVCAR3, OVCAR4, and OVCAR5 best represented the characteristic footprint of mucins
and truncated O-glycans found in SOCs. Strikingly, only OVCAR3 and OVCAR4 expressed MUC16
at levels similar to SOCs (i.e., >75% of cancer cells stained). In the literature there are few studies
reporting on MUC16 expression in OVCA cell lines. In two of these studies, results were obtained by
flow cytometry using OVCAR3 and SKOV3 cell lines and corroborate our results regarding MUC16
expression [22,23]. A larger OVCA cell line study was performed by Lee et al. [24], wherein the
expression of commonly used biomarkers to identify different carcinoma histological subtypes in
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31 cell lines was assessed in 2D and 3D conditions. The MUC16 expression results obtained by
immunocytochemistry are concordant with our findings, reporting a percentage of less than 30% of
epithelial ovarian cancer cell lines positive for MUC16 [24]. MUC16 expression is a hallmark of ovarian
neoplasms of serous origin, widely used in serum detection assays as a marker of disease progression
and response to therapy in the OVCA setting [25]. Importantly, truncated O-glycans are selectively
found on circulating MUC16 in cancer patients and not in benign conditions [26]. The reason for a loss
of MUC16 expression in most OVCA cell lines is unknown, but this is an observation that needs to be
taken into account when using cell lines as surrogates for primary SOCs.
The pattern of expression of mucins and truncated O-glycans observed in this panel of OVCA cell
lines was not related to the reported site of origin of each cell line since similar features were observed in
OVCA cell lines generated from cells collected in different peritoneal cavity sites. Since “solid tumours”
and floating cell clusters present in the ascitic fluid have different protein expression profiles and are
at different stages of the metastatic process [27], it would be anticipated that cell lines derived from
solid tumours (primary tumours or peritoneal implants) or from the peritoneal fluid would mirror
the characteristics from the site of origin. Using an innovative microfluidic chip, Peterson et al. [28]
found that several markers present in solid tumours had different expression levels in cancer cells
present in the peritoneal fluid. For example, they found low levels of certain markers that have been
gaining traction as drug targets (EphA2), or that have been touted as specific for (MUC16 and FOLR1)
or overabundant (Mesothelin) in ovarian cancer [28].
Another parameter that we evaluated was the influence of different culture conditions in the
expression levels of mucins and truncated O-glycans. Three-dimensional cultures are now widely
accepted as cellular models of intermediate complexity between in vivo and in vitro monolayers [24,29].
In our study, MUC1 and T expression were higher in 3D than in 2D cultures, with two OVCA cell lines
shifting from negative in 2D to positive in 3D conditions for both markers. In fact, by reproducing
some of the morphological and functional features of the original tissue, 3D cultures have been used as
a better cellular model to predict epithelial ovarian cancer outcomes [24,30]. Still, our results showed
that the expression pattern of OVCA cell lines cultured in 3D is far from that presented by SOC
regarding MUC16, MUC1, Tn, STn, and T expression. We are now at work on prospective studies to
evaluate paired samples of OVCA and cancer cell aggregates in the peritoneal fluid, where we will
also assess the effect of culturing cells for short and long time periods.
Additionally, it will be relevant to perform peritoneal implantation of primary tumour tissue
samples for comparison with our current cell line models.
The expression of Tn and STn truncated O-glycans is widely reported as a cancer-associated
phenotype in several human cancers, including OVCA, with prognostic implications [31–35]. However,
the effects of expression of truncated Tn and STn O-glycans in OVCA is poorly explored. Since most cell
lines that we evaluated lack the truncated O-glycan signature of SOC, we decided to use a genetically
engineered cell model to study effects. We demonstrated that OVCAR3 SC exhibit decreased cell
proliferation and increased apoptosis compared to parental OVCAR3 cells. These findings are in
agreement with the results by Chou et al. [36], who found that the knockdown of the C1GalT1 enzyme
leads to decreased growth of OVCA cells [36]. Moreover, we found that OVCAR3 SC, despite increased
cell migration, also exhibit a reduction in the mesothelial clearance capacity and form smaller and less
invasive tumours in the mice model. Several studies reported that the expression of STn truncated
O-glycans is more frequently observed at the invasive front of ovarian tumours, but less often in
metastatic lesions [34,37]. Thus, we speculate that the expression of Tn and STn O-glycans facilities the
detachment of individual cells from the primary ovarian tumour by reducing cell–cell aggregation
(Figure S3); however, this may not improve the settlement of metastatic cells at secondary sites. On the
contrary, Radhakrishnan and co-workers, using a similar strategy in a pancreatic cancer cell line (T3M4),
found that the T3M4 SC with truncated O-glycans exhibited enhanced proliferation and oncogenic
features, including enhanced invasive properties in culture, and enhanced growth and invasion in
xenografts [38]. The differences in effects in the two model systems may reflect the differences in
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tumour type or cell lines. In the particular case of ovarian cancer, where peritoneal dissemination is
seeded mainly by transcelomic homing of tumour aggregates, the role of truncated O-glycans can
be diverse.
Optimal research results rely on the selection of cellular models capable of reproducing the
characteristics of the tumour of origin. The expression of MUC16, MUC1, Tn, STn, and T is a footprint
in SOC. Therefore, when studying mucins and truncated O-glycans, the selection of OVCA cell lines
that reflect this phenotype is crucial to explore the putative role of each biomarker in the SOC setting.
The very limited expression of MUC16 in the majority of SOC cell lines was remarkable since it
represents the major ovarian cancer biomarker. Despite the inherent limitations of using cell lines as
surrogate models of complex biological entities such as tumours, we showed that in 3D conditions cells
presented an expression phenotype closer to tumours than cells in monolayers. Finally, we observed
that the homogeneous expression of Tn and STn O-glycans in OVCA cells, using the COSMC KO
strategy, did not intensify oncogenic features either in vitro or in vivo, in contrast to results observed
in other tumour contexts.
4. Materials and Methods
4.1. Cell Lines Culture
Ovarian cancer cell lines were cultured under standard conditions in RPMI 1640 (Thermo Fisher
Scientific, Waltham, MA, USA) containing 10% foetal bovine serum (FBS) (Biowest Nuaillé, France)).
Normal immortalized mesothelial cell line MeT5A (ATCC, American Type Culture Collection) was
maintained in Medium 199 (Thermo Fisher Scientific) containing 10% FBS, 3.3 nM epidermal growth
factor (EGF) (PeproTech, London, UK), 400 nM hydrocortisone (Sigma, St. Louis, MO, USA), 870 nM
Bovine insulin (Sigma) and 20 nM HEPES (Thermo Fisher Scientific). Cell lines were maintained at
37 ◦C and 5% CO2. All cell lines were authenticated using short tandem repeat (STR) profiling and
regularly tested for the absence of mycoplasma. For the 3D cultures, polyHEMA (Poly(2-hydroxyethyl
methacrylate)) (Sigma) coated plates were prepared by dissolving 120 mg/mL of polyHEMA in 95%
ethanol, then adding 100 µL of the solution to 96-well round-bottom plates and drying for 48 h at 55 ◦C.
Ovarian cancer aggregates were generated by plating 4 × 103 cells per well and incubated for four days.
4.2. Cell Microarray (CMA) Construction and Immunocytochemistry
2D cultures were collected by scraping cells from the flask with PBS 1× and 3D cultures were
simply aspirated from each well, followed by centrifugation and fixation with 10% neutral-buffered
formalin. After fixation, cell pellets were embedded in HistoGel (Thermo Fisher Scientific) according to
the manufacturer’s instructions, followed by standard histological processing and paraffin embedding.
Each cell line block (donor block) was sectioned and stained with haematoxylin and eosin (H&E) for
morphology control. Cell microarray (CMA) was designed and constructed by adding one core (1.5 mm
in diameter) from each donor block to a recipient paraffin block. Tumour tissue cores were included as
controls. After construction, CMA was homogenized at 37 ◦C overnight and sectioned with a standard
microtome at 3- to 4-µm thickness. After deparaffinization, heat-induced (98 ◦C) antigen retrieval was
performed with a citrate buffer (pH 6.0) (Thermo Fisher Scientific), and slides were incubated with
hydrogen peroxide 3%. CMAs were immunostained with monoclonal antibodies for MUC16 (5E11) [39]
and M11 (Dako-Agilent, Santa Clara, CA, USA), MUC1 (HMFG2) [40], Tn (5F4) [41], STn (TKH2) [42],
and T (3C9) [43]. Undiluted hybridoma culture supernatants (5E11, HMFG2, 5F4, TKH2 and 3C9) and
M11 diluted at 1/60 in antibody diluent (Thermo Fisher Scientific) were incubated for 1 h at room
temperature (RT). Primary antibodies were detected using a secondary antibody with HRP polymer
(Dako) and visualization of the reaction was performed using diaminobenzidine according to the
manufacturer’s instructions. Immunocytochemistry were evaluated by three independent observers
(LD, SR, and RC), who registered cytolocalization of the staining and the percentage of cells stained
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(0–10%, >10–25%, >25–50%, >50–75%, and >75%). When less than 10% of cells were stained, cases were
considered negative.
4.3. Generation of MeT5A Clones Stable Expressing EGFP Protein
The generation of MeT5A clones stably expressing EGFP protein was achieved by the transfection
of the pEGFP-C1 vector (BD Biosciences, Franklin Lakes, NJ, USA) using Lipofectamine 2000 reagent
(Thermo Fisher Scientific). Selection was initiated 48 h after transfection in a medium supplemented
with 0.3 mg/mL of Geneticin (G418) (Thermo Fisher Scientific). Neomycin-resistant positive clones
obtained through limiting dilution were routinely maintained with 0.1 mg/mL of G418.
4.4. Apoptosis Assay
Cell apoptosis was measured by flow cytometry using the Annexin V-FITC apoptosis detection
kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Briefly, cells were seeded in
six-well plates at the density of 4× 105 cells per well and incubated for different times (24, 48, and 72 h).
After the incubation time, floating and adherent cells were harvested, pelleted by centrifugation,
and suspended in 400 µL of binding buffer. One aliquot of 195 µL of each sample was first stained with
5 µL of Annexin V-FITC, in the dark, for 10 min and then with 10 µL of propidium iodide (20 µg/mL).
Samples were read in a BD Accuri™ C6 (BD Biosciences) flow cytometer, and analysis was performed
using the FlowJo software (Ashland, OR, USA).
4.5. Proliferation Assay
Cell proliferation was evaluated by measuring 5-Bromo-2′-deoxyuridine (BrdU) incorporation
during DNA synthesis, following the manufacturer’s instructions (BrdU labelling and detection kit 1,
Roche, Basel, Switzerland). Briefly, cells were seeded in six-well plates at a density of 4 × 105 cells per
well and incubated for different times (24, 48, or 72 h). After the incubation time, cells were gently
washed in PBS and BrdU was added to each well at a final concentration of 10 µM before incubating
for 1 h at 37 ◦C. Immediately after incubation, the cells were harvested, washed with PBS, and fixed
in ice-cold methanol for 30 min. This was followed by treatment with HCl (Thermo Fisher Scientific)
at 4 M for 20 min. BrdU detection was performed using monoclonal antibody against BrdU (1/20)
(Bu20a, Dako), diluted in PBS containing 0.5% Tween 20 (Sigma) and 0.05% BSA (Sigma) for 1 h
at RT. After that, cells were further washed with PBS and incubated with the secondary antibody
labelled with FITC (1/200, polyclonal rabbit anti-mouse immunglobulin/FITC, Dako) for 30 min
at RT. Unstained cells and cells stained only with the secondary antibody were used as a control.
Data acquisition was performed using a BD Accuri™ C6 (BD Biosciences) flow cytometer, and the
analysis was performed using the FlowJo software.
4.6. Wound Healing Assays
The wound healing assays were performed using silicone culture inserts (Ibidi, Planegg, Germany).
These silicone inserts contain two cell culture reservoirs, separated by a 500-µm wall. Briefly, the inserts
were allowed to attach to the surface of the wells for 30 min at room temperature. Then, 6 × 104
cells were plated in each reservoir and incubated for 24 h at 37 ◦C to reach confluence. After the
incubation time, inserts were removed, followed by a gentle wash with PBS, and 2 mL of culture media
supplemented with 5% FBS (Biowest) were added. Phase contrast images were acquired every 2 h
over a 10-h period at 40×magnification using an Olympus CKX41 inverted microscope. The closing
area was quantified using Fiji software (Madison, WI, USA).
4.7. Matrigel Invasion Assays
The Matrigel invasion assays were performed using BD BioCoat Matrigel invasion chamber inserts
(BD Biosciences) according to the manufacturer’s instructions. Briefly, Matrigel-coated inserts were
Int. J. Mol. Sci. 2018, 19, 2045 10 of 13
pre-incubated for 1 h with serum-free RPMI before adding the ovarian cancer cells. A total of 5 × 104
cells were seeded in the upper chamber in 500 µL of RPMI supplemented with 1% FBS. In the lower
compartment was added 750 µL of RPMI containing 10% FBS as a chemoattractant. Then, cells were
incubated at 37 ◦C and allowed to invade through the Matrigel barrier for 24 h. Following incubation,
non-invasive cells were removed with a cotton swab, whereas invasive cells were fixed in ice-cold
methanol for 10 min. The membranes were carefully cut and mounted on microscope slides with
Vectashield with DAPI (Vector, Burlingame, CA, USA). The number of invasive cells was counted in
an inverted fluorescence microscope (Zeiss Axio Imager Z1, Oberkochen, Germany), and images were
acquired using Axiovision software (Oberkochen, Germany) at 200×magnification.
4.8. Mesothelial Clearance Assay
The mesothelial clearance assays were performed based on a protocol previously described [44]
with minor alterations. MeT5A cells stably expressing EGFP protein were seeded in eight-well
chambers (Ibidi) coated with 10 µg/mL of collagen type I (Millipore, Burlington, MA, USA) and
5 µg/mL of fibronectin (Sigma) and incubated for 24 h to form confluent monolayers. In parallel,
aggregates of ovarian cancer cells were generated by seeding 350 cells per well in 96-well plates with
a round bottom preciously coated with polyHEMA. After incubating for 24 h, the OVCA aggregates
were transferred to the wells containing the mesothelial monolayers. Using the inverted motorized
epifluorescence microscope Leica DMI 6000-time lapse, live cell imaging was performed for 24 h.
To quantify the mesothelial clearance area, the non-fluorescent surface created by the invading ovarian
cancer aggregate in the EGFP mesothelial monolayer was measured at 18 h of co-culture and divided
by the initial two-dimensional area of the aggregate at the initial seeding time. All measurements were
taken using the Fiji software. More than eight multicellular aggregates were imaged by each cell line
in each experiment in a total of three biological experiments.
4.9. Establishment of I.P. Xenograft Models in Nude Mice
All procedures in animals were performed in accordance with the European Guidelines for the
Care and Use of Laboratory Animals, Directive 2010/63/UE, Portuguese National Regulation published
in 2013 (Decreto-Lei n.8 113/ 2013 de 7 de Agosto) and approved by the local Ethics Committee of
the Instituto de Investigacão e Inovação em Saúde- i3S (Porto, Portugal). Project identification code
0421/000/000/2017, date (24/05/17). The authors involved in these experiments have an accreditation
for animal research given from the Portuguese Veterinary Board (Ministerial Directive 1005/92).
NIH(S)II: nu/nu mice, strain described by [45] were generated under Ipatimup supervision. Mice were
monitored for two weeks and kept for an experimental period of eight weeks. To generate i.p. xenografts
of OVCAR3 and OVCAR3 SC, 2 × 107 cells in 200 µL of PBS were injected intraperitoneally in a total of
five mice per cell line. Animals were monitored twice a week. At the end of the experimental period
(eight weeks), mice were humanely euthanized (with anaesthesia followed by cervical dislocation)
and necropsies performed. Animal organs were harvested for histological processing, embedding,
and sectioning. H&E stain was performed in slides from all tissue blocks to evaluate tumour localization,
growth, and invasion.
4.10. Statistics
Each experiment was carried out in triplicate in at least two independent experiments, and data
were expressed as mean ± SD. Statistical analysis was performed using Student’s t-test. A value of
p < 0.05 was considered significantly different.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
2045/s1.
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Abbreviations
SOC Serous ovarian carcinoma
2D Two-dimensional
3D Three-dimensional
OVCA Ovarian cancer
SC Simple cells
PBS Phosphate-buffered saline
SD Standard deviation
EGFP Enhanced green fluorescent protein
DAPI 4′,6-Diamidino-2-Phenylindole, Dihydrochloride
FBS Fetal bovine serum
DNA Deoxyribonucleic acid
FITC Fluorescein isothiocyanate
BrdU 5-Bromo-2′-deoxyuridine
G418 Geneticin
CMA Cell microarray
H&E Haematoxylin and eosin
STR Short tandem repeats
EGF Epidermal growth factor
HRP Horseradish peroxidase
C1GalT1 β1,3-galactosyltransferase
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